Citius Oncology (CTOR) Competitors $1.57 +0.03 (+1.95%) Closing price 04:00 PM EasternExtended Trading$1.51 -0.06 (-3.76%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CTOR vs. BHVN, EVO, ETNB, JANX, ANIP, EWTX, MESO, TVTX, CVAC, and CALTShould you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Biohaven (BHVN), Evotec (EVO), 89BIO (ETNB), Janux Therapeutics (JANX), ANI Pharmaceuticals (ANIP), Edgewise Therapeutics (EWTX), Mesoblast (MESO), Travere Therapeutics (TVTX), CureVac (CVAC), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Citius Oncology vs. Its Competitors Biohaven Evotec 89BIO Janux Therapeutics ANI Pharmaceuticals Edgewise Therapeutics Mesoblast Travere Therapeutics CureVac Calliditas Therapeutics AB (publ) Citius Oncology (NASDAQ:CTOR) and Biohaven (NYSE:BHVN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends. Which has stronger earnings & valuation, CTOR or BHVN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius OncologyN/AN/AN/AN/AN/ABiohavenN/AN/A-$846.42M-$9.36-1.43 Is CTOR or BHVN more profitable? Citius Oncology's return on equity of -53.88% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets Citius OncologyN/A -53.88% -18.86% Biohaven N/A -257.07%-164.01% Do insiders and institutionals believe in CTOR or BHVN? 70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 4.6% of Citius Oncology shares are held by insiders. Comparatively, 14.6% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, CTOR or BHVN? Citius Oncology has a beta of 3.06, meaning that its share price is 206% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Does the media refer more to CTOR or BHVN? In the previous week, Biohaven had 9 more articles in the media than Citius Oncology. MarketBeat recorded 15 mentions for Biohaven and 6 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.77 beat Biohaven's score of 0.31 indicating that Citius Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 3 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer CTOR or BHVN? Citius Oncology currently has a consensus target price of $3.00, indicating a potential upside of 91.08%. Biohaven has a consensus target price of $58.46, indicating a potential upside of 337.78%. Given Biohaven's stronger consensus rating and higher probable upside, analysts clearly believe Biohaven is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Biohaven 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.07 SummaryBiohaven beats Citius Oncology on 7 of the 11 factors compared between the two stocks. Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTOR vs. The Competition Export to ExcelMetricCitius OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$112.33M$2.93B$5.57B$9.31BDividend YieldN/A2.43%4.23%4.03%P/E RatioN/A20.5028.6119.73Price / SalesN/A267.14411.30174.40Price / CashN/A43.1536.0257.96Price / Book2.457.768.235.67Net IncomeN/A-$55.11M$3.23B$257.79M7 Day Performance-63.82%0.96%0.01%0.54%1 Month Performance12.95%8.45%5.63%8.86%1 Year PerformanceN/A-2.37%26.55%14.22% Citius Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTORCitius Oncology1.6704 of 5 stars$1.57+1.9%$3.00+91.1%N/A$112.33MN/A0.00N/ANews CoverageGap DownHigh Trading VolumeBHVNBiohaven3.3538 of 5 stars$13.81-5.6%$58.46+323.3%-65.5%$1.49BN/A-1.48239Trending NewsEVOEvotec1.979 of 5 stars$4.18-0.5%$5.93+41.9%-13.8%$1.49B$862.40M0.004,827ETNB89BIO1.8131 of 5 stars$10.22+0.6%$26.43+158.6%+16.8%$1.48BN/A-3.0240JANXJanux Therapeutics2.6808 of 5 stars$23.96-2.0%$95.25+297.5%-40.7%$1.45B$9.34M-17.6230News CoverageANIPANI Pharmaceuticals3.735 of 5 stars$64.91-0.6%$80.13+23.4%+1.2%$1.41B$674.07M-51.11600News CoverageAnalyst RevisionEWTXEdgewise Therapeutics1.4605 of 5 stars$12.61-3.2%$40.00+217.2%-41.5%$1.37BN/A-8.1460MESOMesoblast2.1946 of 5 stars$10.53-1.4%$18.00+70.9%+43.3%$1.36B$5.90M0.0080Positive NewsGap UpTVTXTravere Therapeutics3.7944 of 5 stars$14.60-2.7%$32.14+120.2%+67.0%$1.33B$233.18M-5.20460Positive NewsAnalyst RevisionCVACCureVac4.7222 of 5 stars$5.41-0.7%$6.83+26.3%+50.3%$1.22B$579.18M5.88880Positive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies Biohaven Competitors Evotec Competitors 89BIO Competitors Janux Therapeutics Competitors ANI Pharmaceuticals Competitors Edgewise Therapeutics Competitors Mesoblast Competitors Travere Therapeutics Competitors CureVac Competitors Calliditas Therapeutics AB (publ) Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTOR) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTOR Stock Alerts